NCT05056441 (EVOLVE) is a clinical trial in Crohn Disease, sponsored by Takeda.

Who is sponsoring NCT05056441?

NCT05056441 is sponsored by Takeda.

What condition does NCT05056441 study?

NCT05056441 studies Crohn Disease.

Is NCT05056441 still recruiting?

NCT05056441 is currently completed. Last updated 21 October 2022.

Last reviewed 2022-10-21 · How we verify

NCT05056441: EVOLVE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Real-World Outcomes of People With Crohn's Disease (CD)

Completed Last updated 21 October 2022

What this trial tests

trial in Crohn Disease in 623 participants. Completed in 30 September 2022.

Timeline

1 December 2021

Primary endpoint
30 September 2022

30 September 2022

Quick facts

Lead sponsor	Takeda
Status	Completed
Study type	OBSERVATIONAL
Enrollment	623
Start date	1 December 2021
Primary completion	30 September 2022
Estimated completion	30 September 2022
Sites	31 locations across Belgium, Switzerland, Australia

Conditions studied

Crohn Disease — all drugs for Crohn Disease →

Sponsor

Takeda — full company profile →

Who can join

18 and older, any sex, with Crohn Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main aim of this study is to compare long-term remission in participants receiving vedolizumab (VDZ) and those receiving ustekinumab (UST). In this study, the study doctors will review each participant's past medical records. This study is about collecting existing information only; participants will not receive treatment or need to visit a study doctor during this study.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Real-World Clinical Effectiveness and Safety of Vedolizumab and Ustekinumab in Biologic-Naïve Patients With Early or Late Crohn's Disease: Results From the EVOLVE Expansion Study.
Christensen B, Scharl M, Bressler B, Khan Z, et al · · 2025 · cited 1× · PMID 40641824 · DOI 10.1093/crocol/otaf031
Real-world clinical effectiveness and safety of vedolizumab and ustekinumab in biologic-naive patients with noncomplicated or complex Crohn's disease: results from the EVOLVE Expansion study.
Ferrante M, Christensen B, Bressler B, Bassel M, et al · · 2026 · PMID 42065987 · DOI 10.1097/meg.0000000000003193
Real-World Effectiveness and Safety of Vedolizumab and Ustekinumab in Biologic-Naive Patients With Crohn's Disease: Results From the EVOLVE Expansion Chart Review Study.
Ferrante M, Christensen B, Bressler B, Brett NR, et al · · 2026 · PMID 41729856 · DOI 10.1097/mcg.0000000000002350

Verify or expand the search:

Other recruiting trials for Crohn Disease

Currently open trials in the same condition.

NCT06953791 — Comparison of Quality of Life During a Flare of Crohn's Disease Treated With Prednisolone or aCDED With PEN in Adult Pat · Phase 2 · recruiting
NCT07310095 — A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD) · Phase 4 · recruiting
NCT07364734 — Epidemiological Characteristics and Efficacy Evaluation of Difficult-To-Treat Crohn's Disease · recruiting
NCT07170462 — Cranberry and Gut Health in Crohn's Disease · EARLY_PHASE1 · recruiting
NCT07196722 — A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease · Phase 2, PHASE3 · recruiting

Other Takeda trials

Trials by the same sponsor.

NCT05669729 — A Survey to Assess Participants', Caregivers', and Nurses' Use and Understanding of Educational Material on Velagluceras · not yet recruiting
NCT07403968 — A Study of Zasocitinib (TAK-279) in Adults With Active Crohn's Disease · Phase 2 · not yet recruiting
NCT07293364 — A Study to Learn About the C1-Inhibitor Function as Diagnosis for Hereditary Angioedema · NA · not yet recruiting
NCT07218393 — A Study About the Diagnosis and Management of Hereditary Angioedema (HAE) in Egypt · not yet recruiting
NCT07445087 — A Study of Takhzyro in Teenagers and Adults With Hereditary Angioedema (HAE) in South Korea · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05056441 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Takeda
Last refreshed: 21 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05056441.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing